Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFranklin Glb Tr Regulatory News (FRGT)

  • This share is currently suspended. It was suspended at a price of 350.00
  • There is currently no data for FRGT

Combination with IGET

13 Nov 2025 09:33

RNS Number : 4280H
Franklin Global Trust PLC
13 November 2025
Β 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTOΒ THE UNITED STATES, AUSTRALIA,Β CANADA,Β JAPAN,Β NEW ZEALAND, THE REPUBLIC OFΒ SOUTH AFRICA, IN ANY MEMBER STATE OF THE EEAΒ OR IN ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in any jurisdiction in which the same would be unlawful. Neither this announcement nor any part of it shall form the basis of or be relied on in connection with or act as an inducement to enter into any contract or commitment whatsoever.

This announcement contains information that is inside information for the purposes of Article 7 of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended (the Market Abuse Regulation).

13 November 2025

Β 

Franklin Global Trust plc

Legal Entity Identifier: 549300RKB85NFVSTBM94

Combination withΒ Invesco Global Equity Income Trust plcΒ ("IGET")

Introduction

The Board of Franklin Global Trust plc (the "Company" or "FRGT") is pleased to announce that heads of terms have been agreed for a combination of the Company and IGET (the "Combination"). The Combination will be implemented through a scheme of reconstruction of the Company under section 110 of the Insolvency Act 1986 (the "Scheme"), under which the Company's shareholders ("Shareholders") will be entitled to elect to receive new shares inΒ IGET and/or cash.

Invesco Fund Managers Limited ("Invesco") will continue to manage the enlargedΒ IGET's portfolio in accordance withΒ IGET's existing investment objective and investment policy.

Β 

Benefits of the Combination

The Board believes the Combination should deliver the following benefits for Shareholders:

Β· Strong absolute and relative investment performance:Β 

For periods to 31 October 2025

oΒ  IGET has outperformed all Global Equity Income peers[1] over three and five years and has outperformed all Global Equity peers[2] over five years, in both net asset value ("NAV") and share price total returns.

oΒ  IGET has delivered NAV total returns of 74.5 per cent. and 140.3 per cent. over three and five years respectively, outperforming its benchmark (the MSCI World Index) total returns of 57.9 per cent. and 103.0 per cent. over the corresponding periods.

oΒ  IGET has delivered share price total returns of 103.1 per cent. and 152.0 per cent. over three and five years respectively.

Past performance is not a guide to the future.

Β· Access to the market leading resources of Invesco:

oΒ  The enlarged IGET is managed by Invesco, a subsidiary of Invesco Limited, a global asset manager with US$2.1 trillion of AUM, including US$32.2 billion managed by the Invesco Global Equities team (as at 30 September 2025).

oΒ  IGET benefits from the expertise of its award-winning Portfolio Managers, Stephen Anness and Joe Dowling, and from the depth of resource and experience offered by the wider Global Equities team.

Β· Improved share rating: Shareholders are expected to benefit from an immediate uplift in value should the relative trading levels continue, withΒ IGETΒ currently trading on a premium NAV ofΒ 1.9Β per cent compared to FRGT's discount to NAV of (2.6) per cent[3].

Β· Scale: It is expected that the Combination will deliver a significant increase in the size of the enlarged IGET, with net assets of up to Β£445 million following the Combination, depending on cash elections. With greater scale, the enlarged IGET is expected to appeal to a broader range of investors, which should result in higher trading volume and market liquidity in the enlarged IGET's shares compared to either FRGT or IGET historically.

Β· Enhanced dividend: IGET has adopted and will maintain an enhanced dividend policy, which pays an annual dividend of at least 4 per cent. of the unaudited previous year-end NAV, paid quarterly in equal amounts.

Β· Opportunity for full cash realisation:Β Shareholders will have the opportunity to elect to realise some or all of their holding for cash, should they not wish to roll over into IGET.

Β· Cost Contributions: Shareholders opting for the Rollover Option (as defined below) should be largely insulated from the costs of the Scheme because of the Cost Contributions (as defined below), as a result of which any impact to NAV per share for shareholders of the enlargedΒ IGET is expected to be immaterial.

Β· Tax-efficient rollover: UK Shareholders will have the opportunity to roll over their investment from the Company to IGET without triggering a capital gains tax charge, subject to the customary tax clearances being received.

Β 

Background to the Combination

The Board has been conscious for some time of the challenges facing the Company, most notably disappointing investment performance and diminishing size.

The Company's performance has had a significant impact on demand for the Company's shares, which, given the Company's zero discount policy, has resulted in the Company repurchasing a significant number of its own shares. This has had a material impact on the size of the Company, with the Company's market capitalisation reducing from Β£300 million to Β£182 million over the last five years[4].

After consulting with the Company's major Shareholders about their objectives for their holdings in the Company, the Board conducted a thorough review of the Company's investment management arrangements, with proposals sought from a number of parties. The Board believes that, among the options considered, the proposal put forward by IGET offers significant benefits and that the Combination represents the most compelling outcome for Shareholders.

Β 

The Scheme

The Scheme will be effected by way of a scheme of reconstruction of the Company under section 110 of the Insolvency Act 1986, resulting in the voluntary liquidation of the Company and the transfer of certain of the Company's assets toΒ IGET in consideration for the issue of new ordinary shares ofΒ IGET ("NewΒ IGET Shares") to Shareholders who elect to roll over intoΒ IGET. The number of NewΒ IGET Shares issued to Shareholders will be determined on a formula asset value ("FAV") for FAV basis.

The Scheme will be subject to,Β inter alia, the approval of both the Company's andΒ IGET's shareholders, in addition to tax clearances and regulatory approvals. Subject to, and conditional on, the Scheme becoming unconditional, qualifying Shareholders will be entitled to elect to receive in respect of some, or all, of their FRGT shares:

i. NewΒ IGETΒ Shares ("Rollover Option"); and/or

ii. cash (the "Cash Option"). The Cash Option will be unlimited, with all valid elections accepted.

NewΒ IGET Shares will be issued as the default option under the Scheme in the event that Shareholders do not make a valid election under the Scheme or only elect for the Cash Option in respect of a portion of their shares. The Cash Option will be offered at a discount of 2 per cent. to the FRGT FAV per share (the "Cash Option Discount").

In accordance with customary practice for such transactions involving investment trusts, the City Code on Takeovers and Mergers is not expected to apply to the Scheme.

Β 

The Cost Contributions

Each company will bear its own costs relating to the Scheme, with the enlarged IGET bearing any stamp duty or listing costs relating to the New IGET Shares.Β 

The benefit of the Cash Option Discount will be allocated first to payΒ FRGT's costs, with any balance of the Cash Option Discount allocated to the benefit of the enlarged IGET.

Invesco has agreed to make a contribution to the costs of the Scheme equivalent to twelve months' management fee on the value of the assets, as at the calculation date, to be transferred toΒ IGET pursuant to the Scheme (the "Invesco Cost Contribution"). The Invesco Cost Contribution will be allocated first to payΒ IGET's costs, with any balance of the Invesco Cost Contribution allocated to the benefit of the enlarged IGET.

It is expected that the benefit of the Invesco Cost Contribution and the Cash Option Discount (together the "Cost Contributions") should mean that Shareholders opting for the Rollover Option will suffer little or no NAV dilution.

Β 

Board structure

Following completion of the Scheme, it is expected that FRGT's Chairman, Christopher Metcalfe, will join theΒ Board ofΒ IGET.

Β 

Discount management

The Company's zero discount policy, which has the objective of providing Shareholders, in normal market conditions, with assurance that the Company's share price is in continuing alignment with the prevailing net asset value per share, will continue until either the current authority is fully utilised or, if earlier, the first Scheme general meeting. Should the authority be fully utilised before the Scheme effective date the Company will not seek to renew the authority given the upcoming cash exit opportunity which is on offer as part of the Scheme.

As announced in IGET's annual report, the IGET Board will continue, in normal market conditions, to actively use its authority to issue or buy-back shares to manage the volatility of the premium or discount. The enlarged IGET will use its buyback authorities with the objective of maintaining a discount no wider than mid-single digits on a sustained basis.

Β 

Expected timetable

In light of the Prospectus Regulation Rules change in January 2026, in order to achieve cost savings, it is intended that the documentation in connection with the Scheme will be posted to each ofΒ IGET's and FRGT's shareholders inΒ January 2026 after the changes to the Prospectus Rules become effective with a view to convening general meetings thereafter. The Scheme is expected to be effective in February 2026.

Β 

Christopher Metcalfe, Chairman ofΒ Franklin Global Trust plc, said:

'The Board undertook a thorough review of all available options for the Company's future. We believe IGET's proposal offers many attractive features, including enhanced scale, improved liquidity, a strong record of investment performance, as well as a full cash alternative for Shareholders. The Board intends to roll its holdings into the new, enlarged IGET vehicle and looks forward to the future with confidence.'

Enquiries:

Β 

Franklin Global Trust plc

Christopher Metcalfe, Chairman

Β 

c/o J.P. Morgan Cazenove

J.P. Morgan Cazenove (Sole Financial Adviser)

William Simmonds

Rupert Budge

Β 

+44 (0) 20 3493 8000

Β 


[1] Those investment companies in the AIC's Global Equity Income sector.

[2] Those investment companies in the AIC's Global Equity sector.

[3] As at close of market on 11 November 2025

[4] From 11 November 2020 to 11 November 2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
UPDUOOKRVRUAARA
Date   Source Headline
15th Dec 20254:51 pmRNSTransaction in Own Shares
15th Dec 20259:30 amRNSNet Asset Value(s)
12th Dec 20254:52 pmRNSTransaction in Own Shares
12th Dec 20253:21 pmRNSInvestment management arrangements
12th Dec 20259:36 amRNSNet Asset Value(s)
11th Dec 20254:50 pmRNSTransaction in Own Shares
11th Dec 20258:22 amRNSNet Asset Value(s)
10th Dec 20255:00 pmRNSTransaction in Own Shares
10th Dec 20258:58 amRNSNet Asset Value(s)
9th Dec 20254:49 pmRNSTransaction in Own Shares
9th Dec 20259:22 amRNSNet Asset Value(s)
8th Dec 20254:54 pmRNSTransaction in Own Shares
8th Dec 20259:09 amRNSNet Asset Value(s)
5th Dec 20254:51 pmRNSTransaction in Own Shares
5th Dec 20259:15 amRNSNet Asset Value(s)
4th Dec 20255:05 pmRNSTransaction in Own Shares
4th Dec 20257:52 amRNSNet Asset Value(s)
3rd Dec 20254:51 pmRNSTransaction in Own Shares
3rd Dec 20259:51 amRNSNet Asset Value(s)
2nd Dec 20254:52 pmRNSTransaction in Own Shares
2nd Dec 20258:56 amRNSNet Asset Value(s)
1st Dec 20254:57 pmRNSTransaction in Own Shares
1st Dec 202511:42 amRNSTotal Voting Rights
1st Dec 20259:51 amRNSNet Asset Value(s)
28th Nov 20254:49 pmRNSTransaction in Own Shares
28th Nov 202510:10 amRNSNet Asset Value(s)
27th Nov 20254:53 pmRNSTransaction in Own Shares
27th Nov 20252:36 pmRNSDividend Declaration
27th Nov 202510:18 amRNSNet Asset Value(s)
26th Nov 20254:46 pmRNSTransaction in Own Shares
26th Nov 202510:21 amRNSNet Asset Value(s)
25th Nov 20254:52 pmRNSTransaction in Own Shares
25th Nov 20259:04 amRNSNet Asset Value(s)
24th Nov 202510:42 amRNSNet Asset Value(s)
21st Nov 20254:51 pmRNSTransaction in Own Shares
21st Nov 202510:11 amRNSNet Asset Value(s)
20th Nov 20254:54 pmRNSTransaction in Own Shares
20th Nov 20259:44 amRNSNet Asset Value(s)
19th Nov 20259:51 amRNSNet Asset Value(s)
18th Nov 20254:57 pmRNSTransaction in Own Shares
18th Nov 20258:14 amRNSNet Asset Value(s)
17th Nov 20254:57 pmRNSTransaction in Own Shares
17th Nov 20259:55 amRNSNet Asset Value(s)
14th Nov 20254:50 pmRNSTransaction in Own Shares
14th Nov 202510:04 amRNSNet Asset Value(s)
13th Nov 20254:54 pmRNSTransaction in Own Shares
13th Nov 20259:33 amRNSCombination with IGET
13th Nov 20259:17 amRNSNet Asset Value(s)
12th Nov 20254:52 pmRNSTransaction in Own Shares
12th Nov 20258:35 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.